Endo withdraws application for extended Frova use

CHADDS FORD, Pa. Endo Pharmaceuticals has withdrawn its application to extend the use of its migraine drug Frova in short-term prevention of menstrual migraines, according to published reports.

The decision to withdraw the application came after an evaluation of the points raised in a “not approvable” letter issued by the Food and Drug Administration, the company said.

In September 2007, the FDA identified deficiencies and asked for more information regarding Frova for menstrual migraine prevention.